Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
Clin Hematol Int
.
2022 Dec;4(4):148-151.
doi: 10.1007/s44228-022-00016-4.
Epub 2022 Aug 23.
Authors
Shamis Khan
1
,
Sara Taveras Alam
2
3
4
,
Rosa Torres Ramos
2
,
John Etumbani Mbue
2
,
Effrosyni Apostolidou
2
3
4
,
Gustavo A Rivero
2
3
4
,
Sarvari Venkata Yellapragada
2
3
4
Affiliations
1
Department of Medicine, Baylor College of Medicine, Houston, TX, USA. shamis.khan@bcm.edu.
2
Department of Hematology and Oncology, Michael E DeBakey VA Medical Center, Houston, TX, USA.
3
Section of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA.
4
Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA.
PMID:
35997953
PMCID:
PMC9763517
DOI:
10.1007/s44228-022-00016-4
No abstract available